CU20210035A7 - Compuestos de azalactam como inhibidores de hpk 1 - Google Patents

Compuestos de azalactam como inhibidores de hpk 1

Info

Publication number
CU20210035A7
CU20210035A7 CU2021000035A CU20210035A CU20210035A7 CU 20210035 A7 CU20210035 A7 CU 20210035A7 CU 2021000035 A CU2021000035 A CU 2021000035A CU 20210035 A CU20210035 A CU 20210035A CU 20210035 A7 CU20210035 A7 CU 20210035A7
Authority
CU
Cuba
Prior art keywords
sup
compounds
azalactam
hpk
inhibitors
Prior art date
Application number
CU2021000035A
Other languages
English (en)
Inventor
Omar Khaled Ahmad
Bel Matthew L Del
Rebecca Anne Gallego
Mingying He
Mehran Jalaie
Ted William Johnson
Robert Steven Kania
Michele Ann Mctigue
Sajiv Krishnan Nair
Anne-Marie Dechert Schmitt
Jamison Bryce Tuttle
Dahui Zhou
Ru Zhou
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68771726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20210035(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CU20210035A7 publication Critical patent/CU20210035A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

<p>La presente invención se refiere a compuestos de la fórmula general (I)</p> <p>Espacio para la fórmula:</p> <p>y sales de estos aceptables desde el punto de vista farmacéutico, en donde R<sup>1</sup>, R<sup>1</sup><sup>a</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, y (R<sup>5</sup>)<sub>a</sub> son como se definen en la presente, útiles para el tratamiento del crecimiento anormal de células, que incluye cáncer.</p>
CU2021000035A 2018-11-15 2019-11-12 Compuestos de azalactam como inhibidores de hpk 1 CU20210035A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767602P 2018-11-15 2018-11-15
US201962909970P 2019-10-03 2019-10-03
PCT/IB2019/059702 WO2020100027A1 (en) 2018-11-15 2019-11-12 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
CU20210035A7 true CU20210035A7 (es) 2021-12-08

Family

ID=68771726

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000035A CU20210035A7 (es) 2018-11-15 2019-11-12 Compuestos de azalactam como inhibidores de hpk 1

Country Status (38)

Country Link
US (1) US11142525B2 (es)
EP (1) EP3880676B1 (es)
JP (1) JP7118267B2 (es)
KR (1) KR20210090675A (es)
CN (1) CN113316576A (es)
AU (1) AU2019378184B2 (es)
BR (1) BR112021008991A2 (es)
CA (1) CA3061392A1 (es)
CL (1) CL2021001190A1 (es)
CO (1) CO2021006114A2 (es)
CR (1) CR20210251A (es)
CU (1) CU20210035A7 (es)
CY (1) CY1126663T1 (es)
DK (1) DK3880676T3 (es)
DO (1) DOP2021000088A (es)
EC (1) ECSP21034668A (es)
ES (1) ES2958948T3 (es)
FI (1) FI3880676T3 (es)
GE (2) GEP20227434B (es)
HR (1) HRP20231089T1 (es)
HU (1) HUE063367T2 (es)
IL (1) IL283149A (es)
LT (1) LT3880676T (es)
MD (1) MD3880676T2 (es)
MX (1) MX2021005754A (es)
PE (1) PE20211868A1 (es)
PH (1) PH12021551117A1 (es)
PL (1) PL3880676T3 (es)
PT (1) PT3880676T (es)
PY (1) PY1996328A (es)
RS (1) RS64655B1 (es)
SG (1) SG11202104394XA (es)
SI (1) SI3880676T1 (es)
TW (1) TWI718758B (es)
UA (1) UA127426C2 (es)
UY (1) UY38471A (es)
WO (1) WO2020100027A1 (es)
ZA (1) ZA202103099B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI721623B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
TW202136261A (zh) 2018-10-31 2021-10-01 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN114945366B (zh) * 2019-09-13 2025-01-07 林伯士萨顿公司 Hpk1拮抗剂和其用途
CN115698004A (zh) * 2020-05-01 2023-02-03 辉瑞公司 作为hpk1抑制剂的氮杂内酰胺化合物
CN112409268A (zh) * 2020-12-03 2021-02-26 西南交通大学 靶向Fam20C抑制剂的制备及其抗三阴性乳腺癌作用
EP4301756A4 (en) * 2021-03-05 2025-02-26 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
WO2022258044A1 (zh) * 2021-06-11 2022-12-15 杭州中美华东制药有限公司 吡咯并吡啶酮类化合物及其制备方法和用途
WO2023001794A1 (en) 2021-07-20 2023-01-26 Astrazeneca Ab Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
WO2023023942A1 (en) * 2021-08-24 2023-03-02 Biofront Ltd (Cayman) Hpk1 inhibitors, compositions comprising hpk1 inhibitor, and methods of using the same
WO2023030478A1 (zh) * 2021-09-03 2023-03-09 浙江海正药业股份有限公司 吡啶并内酰胺类衍生物及其制备方法和用途
TW202328152A (zh) * 2021-10-05 2023-07-16 美商輝瑞大藥廠 氮雜內醯胺化合物之晶型
CN114767676B (zh) 2022-04-22 2024-04-19 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂在预防和/或治疗人的病原体感染中的应用
KR102855849B1 (ko) 2022-11-25 2025-09-08 충남대학교산학협력단 이미다조피리딘 유도체, 이를 유효성분으로 포함하는 약제학적 조성물 및 이를 이용하는 암의 치료 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5243049A (en) * 1992-01-22 1993-09-07 Neurogen Corporation Certain pyrroloquinolinones: a new class of GABA brain receptor ligands
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
JP5241834B2 (ja) * 2007-07-19 2013-07-17 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としての複素環アミド化合物
WO2018049324A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
WO2018167147A1 (en) 2017-03-15 2018-09-20 F. Hoffmann-La Roche Ag Azaindoles as inhibitors of hpk1
CN109265443B (zh) 2017-07-18 2022-11-29 南京圣和药业股份有限公司 作为ask抑制剂的杂环化合物及其应用
WO2019148005A1 (en) 2018-01-26 2019-08-01 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof

Also Published As

Publication number Publication date
HUE063367T2 (hu) 2024-01-28
MD3880676T2 (ro) 2023-12-31
CY1126663T1 (el) 2026-02-25
PE20211868A1 (es) 2021-09-21
TWI718758B (zh) 2021-02-11
CO2021006114A2 (es) 2021-05-31
SG11202104394XA (en) 2021-05-28
ECSP21034668A (es) 2021-06-30
JP7118267B2 (ja) 2022-08-15
PY1996328A (es) 2021-05-21
UA127426C2 (uk) 2023-08-16
CR20210251A (es) 2021-07-14
RS64655B1 (sr) 2023-10-31
EP3880676B1 (en) 2023-08-02
EP3880676A1 (en) 2021-09-22
AU2019378184B2 (en) 2022-09-15
KR20210090675A (ko) 2021-07-20
DOP2021000088A (es) 2021-06-30
TW202031657A (zh) 2020-09-01
US11142525B2 (en) 2021-10-12
PT3880676T (pt) 2023-10-04
UY38471A (es) 2020-06-30
LT3880676T (lt) 2023-09-25
JP2022507231A (ja) 2022-01-18
HRP20231089T1 (hr) 2023-12-22
CN113316576A (zh) 2021-08-27
MX2021005754A (es) 2021-08-11
ES2958948T3 (es) 2024-02-16
CA3061392A1 (en) 2020-05-15
FI3880676T3 (fi) 2023-09-15
GEAP202215630A (en) 2022-06-27
GEP20227434B (en) 2022-10-25
BR112021008991A2 (pt) 2021-08-10
ZA202103099B (en) 2023-11-29
PH12021551117A1 (en) 2021-11-22
WO2020100027A1 (en) 2020-05-22
CL2021001190A1 (es) 2021-12-24
AU2019378184A1 (en) 2021-05-27
DK3880676T3 (da) 2023-09-04
PL3880676T3 (pl) 2023-12-11
IL283149A (en) 2021-06-30
SI3880676T1 (sl) 2023-10-30
US20200172539A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
CU20210035A7 (es) Compuestos de azalactam como inhibidores de hpk 1
UY38553A (es) Inhibidores de cdk2
CR20200484A (es) COMPUESTOS DE DIHIDROISOQUINOLINONA SUSTITUIDA (Divisional 2016-0574)
ECSP20067394A (es) Inhibidores de cinasa dependientes de ciclina
ECSP21091615A (es) Derivados de benzisoxazol sulfonamida
ECSP24026455A (es) Compuestos de pirrolotriazina como inhibidores de tam
SV2019005836A (es) Inhibidores de piridopirimdinona cdk2/4/6.
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2023001876A (es) Derivados de rapamicina.
MX2022000271A (es) Inhibidores de la quinasa progenitora hematopoyetica 1 y usos de los mismos.
UY37302A (es) Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
UY35630A (es) Carboxamidas primarias como inhibidores de btk
DOP2012000151A (es) Nuevos compuestos triciclicos
CR20170092A (es) Compuestos y composiciones como inhibidores de quinasa raf
CL2022003007A1 (es) Compuestos de azalactama como inhibidores de hpk1
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
CU24661B1 (es) Compuestos de alquinileno sustituidos como agentes anticancerígenos
ECSP23088732A (es) Moduladores de trex1
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.
AR131945A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
PY2153042A (es) Inhibidores de mutación her2
ECSP17003149A (es) Compuestos de dihidroisoquinolinona sustituida
CU20140033A7 (es) Derivados de pirrolopirimidina y purina